Coronavirus Update: Remdesivir Fast-Tracked, GSK's Shingrix Hit Hard By Lockdown
Plus J&J Expands Manufacturing Capacity
Executive Summary
Results from the first major trial of remdesivir are positive, but fail to show clear mortality benefit - making its forthcoming approval just the first step towards winning the war on COVID-19.
You may also be interested in...
Deal Watch: Menarini Enters US Oncology Market Via Merger With Stemline
Menarini/Stemline, Supernus/US WorldMeds, BioMarin/DiNOAQOR, Adicet/ResTORbio, Vertex/Affinia, Hansoh/NiKang, plus COVID-19 deals in brief and more.
EMA Begins Rolling Review Of Remdesivir For COVID-19
Results from the US ACCT study have led both the EMA and the FDA to accelerate the review of Gilead’s remdesivir for use in coronavirus patients. The EMA says it will also take account of the results of a Chinese study that found the antiviral was “not associated with statistically significant clinical benefits.”
Gilead’s Major Challenge Is Sustainable Model For Remdesivir
With efficacy data in hand, Gilead wants to balance economic sustainability with broad availability of remdesivir for COVID-19 patients. The firm did not alter guidance on Q1 earnings call.